buy guidanc street look
achiev margin improv focu
diversif
lower adcetri guidanc vs consensu off-set signific increas
gross-margin pipelin updat consist prior disclosur updat
estim reflect result slightli lower adcetri forecast
off-set lower cog maintain buy rate sinc believ late stage
pipelin gener addl upsid next month pt
adcetri sale in-lin street consensu investor continu worri
growth report revenu beat consensu
estim vs consensu predominantli due higher-than-expect
collabor licens incom vs consensu adcetri sale
in-lin consensu sequenti growth vs europ
market author applic adcetri classic hodgkin lymphoma chl
current review plan submit base data
eu
adcetri guidanc street signific gross margin improv
major posit surpris guid us/canada adcetri net sale
growth come predominantli hl indic
consist forecast street consensu posit
note guid cog go forward due reduct
royalti oblig third parti result net increas free cash flow
pipelin remain track pivot data potenti three program
top-lin result form pivot enfortumab vedotin ev phase ii trial
metastat urotheli cancer muc still guid trial evalu ev
line muc follow treatment checkpoint inhibitor cpi platinum-bas
chemotherapi confirmatori phase trial patient popul
on-going also conduct first-lin trial evalu ev
multipl combin includ keytruda platinum-bas chemotherapi
pend posit data plan file bla acceler approv
pathway also present updat data upcom asco-gu
pivot tucatinib trial track top-lin result guid recal
pivot random phase ii trial evalu tucatinib vs placebo
combin w/ xeloda herceptin third line metastat breast cancer
set guid complet enrol initi plan patient
earli support analysi primari endpoint follow fda
meet last year also increas trial size patient anticip
enrol complet increas power key secondari
endpoint overal surviv os patient brain metastasi
think could strengthen potenti product label
tisotumab pivot studi complet enrol set
stage potenti data pivot phase ii trial patient recurrent-
metastat cervic cancer continu enrol expect top-lin data support
updat phase ib result present esmo link also conduct
phase ib studi platinum-resist ovarian cancer addit phase basket trial
evalu tv solid tumor tissu factor express
page analyst certif import disclosur
earli stage program remain track ladiratuzumab vedotin tv
target liv-ia remain earli stage develop breast cancer
plan submit ind addit development program among out-licens agent
rhhbi submit bla polatuzumab monoclon antibodi r/
rdlbcl pivot data gsk anti-bcma-adc expect
updat estim price target updat estim reflect
financi result guidanc reduc sale forecast adcetri
off-set lower long-term cog assumpt
previous result net increas pt
page analyst certif import disclosur
valuat risk
valu previous per share use dcf base valuat
method lower cost sale cost royalti revenu start
follow financi guidanc provid valuat includ commerci product adcetri
well probability-adjust cash flow deriv compani pipelin use
discount rate consist commerci stage biotech compani
coverag termin growth rate appli termin year post-assum
adcetri biosimilar entri
risk valuat includ regulatori commerci setback potenti
emerg new competitor and/or lower product sale expect risk
intellectu properti risk manag execut misstep
page analyst certif import disclosur
royalti revenu
total cost expens
incom tax
royalti revenu
total cost expens
incom tax
guggenheim secur llc estim sec file
 invest loss loss associ common stock hold
page analyst certif import disclosur
royalti revenu
total cost expens
invest incom loss net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
